吉比特(603444.SH):新產品上線前期會有一定的營銷推廣投入
格隆匯7月4日丨有投資者向吉比特(603444.SH)提問:公司2023年下半年有較多產品的上線計劃,未來銷售費用是否會大額增加?
吉比特回覆:新產品上線前期會有一定的營銷推廣投入,公司會根據遊戲的LTV、產品類型、用户特徵、留存率等多方面因素決定不同產品的買量策略,並根據ROI(投資回報率)進行動態調整。未來銷售費用支出情況受到新產品上線情況、產品特徵、市場環境等多種因素綜合影響,當前階段較難預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.